Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Serum concentration of taurochenodeoxycholic acid predicts clinically significant portal hypertension

K. Žížalová, B. Nováková, M. Vecka, J. Petrtýl, V. Lánská, K. Pelinková, V. Šmíd, R. Brůha, L. Vítek, M. Leníček

. 2023 ; 43 (4) : 888-895. [pub] 20221125

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc23003716

BACKGROUND & AIMS: Severity of portal hypertension is usually quantified by measuring the hepatic venous pressure gradient (HVPG). However, due to its invasiveness, alternative markers are being sought. Bile acids (BA), being synthesized, metabolized, and transported by the liver, seem to have the potential to serve as endogenous markers. The aim of the present study was to determine whether serum BA reflect the severity of portal hypertension. METHODS: We correlated serum concentrations of individual BA with portal pressure (as HVPG) in an exploratory cohort of 21 cirrhotic patients with portal hypertension. The predictive potential of selected candidates was then confirmed in an independent validation cohort (n = 214). Additionally, nine previously published noninvasive markers were added to the stepwise logistic regression model to identify the most relevant ones, which were eventually used to create a prognostic index of portal hypertension. RESULTS: Serum levels of taurochenodeoxycholic acid (TCDCA) significantly correlated with HVPG and showed a high potential to predict clinically significant portal hypertension (HVPG ≥ 10 mm Hg: AUROC = 0.97 ± 0.06). This was confirmed in the validation cohort (AUROC = 0.96 ± 0.01). The predictive index (constructed based on AST/ALT, spleen diameter, and TCDCA concentration) was able to distinguish clinically significant portal hypertension with 95% sensitivity and 76% specificity. CONCLUSIONS: TCDCA seems to be a promising noninvasive marker of clinically significant portal hypertension. Its predictive potential may be further enhanced when it is combined with both the AST/ALT ratio and spleen diameter.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23003716
003      
CZ-PrNML
005      
20230425140826.0
007      
ta
008      
230418s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1111/liv.15481 $2 doi
035    __
$a (PubMed)36433660
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Žížalová, Kateřina $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine and General University Hospital in Prague, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000311554351
245    10
$a Serum concentration of taurochenodeoxycholic acid predicts clinically significant portal hypertension / $c K. Žížalová, B. Nováková, M. Vecka, J. Petrtýl, V. Lánská, K. Pelinková, V. Šmíd, R. Brůha, L. Vítek, M. Leníček
520    9_
$a BACKGROUND & AIMS: Severity of portal hypertension is usually quantified by measuring the hepatic venous pressure gradient (HVPG). However, due to its invasiveness, alternative markers are being sought. Bile acids (BA), being synthesized, metabolized, and transported by the liver, seem to have the potential to serve as endogenous markers. The aim of the present study was to determine whether serum BA reflect the severity of portal hypertension. METHODS: We correlated serum concentrations of individual BA with portal pressure (as HVPG) in an exploratory cohort of 21 cirrhotic patients with portal hypertension. The predictive potential of selected candidates was then confirmed in an independent validation cohort (n = 214). Additionally, nine previously published noninvasive markers were added to the stepwise logistic regression model to identify the most relevant ones, which were eventually used to create a prognostic index of portal hypertension. RESULTS: Serum levels of taurochenodeoxycholic acid (TCDCA) significantly correlated with HVPG and showed a high potential to predict clinically significant portal hypertension (HVPG ≥ 10 mm Hg: AUROC = 0.97 ± 0.06). This was confirmed in the validation cohort (AUROC = 0.96 ± 0.01). The predictive index (constructed based on AST/ALT, spleen diameter, and TCDCA concentration) was able to distinguish clinically significant portal hypertension with 95% sensitivity and 76% specificity. CONCLUSIONS: TCDCA seems to be a promising noninvasive marker of clinically significant portal hypertension. Its predictive potential may be further enhanced when it is combined with both the AST/ALT ratio and spleen diameter.
650    _2
$a lidé $7 D006801
650    12
$a kyselina taurochenodeoxycholová $7 D013655
650    _2
$a jaterní cirhóza $x komplikace $x diagnóza $7 D008103
650    12
$a portální hypertenze $x diagnóza $7 D006975
650    _2
$a játra $7 D008099
650    _2
$a prognóza $7 D011379
650    _2
$a portální tlak $7 D017082
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Nováková, Barbora $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine and General University Hospital in Prague, Charles University, Prague, Czech Republic $u 4th Department of Internal Medicine, First Faculty of Medicine and General University Hospital in Prague, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000275655592
700    1_
$a Vecka, Marek $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine and General University Hospital in Prague, Charles University, Prague, Czech Republic $u 4th Department of Internal Medicine, First Faculty of Medicine and General University Hospital in Prague, Charles University, Prague, Czech Republic
700    1_
$a Petrtýl, Jaromír $u 4th Department of Internal Medicine, First Faculty of Medicine and General University Hospital in Prague, Charles University, Prague, Czech Republic
700    1_
$a Lánská, Věra $u Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Pelinková, Květa $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine and General University Hospital in Prague, Charles University, Prague, Czech Republic
700    1_
$a Šmíd, Václav $u 4th Department of Internal Medicine, First Faculty of Medicine and General University Hospital in Prague, Charles University, Prague, Czech Republic
700    1_
$a Brůha, Radan $u 4th Department of Internal Medicine, First Faculty of Medicine and General University Hospital in Prague, Charles University, Prague, Czech Republic
700    1_
$a Vítek, Libor $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine and General University Hospital in Prague, Charles University, Prague, Czech Republic $u 4th Department of Internal Medicine, First Faculty of Medicine and General University Hospital in Prague, Charles University, Prague, Czech Republic
700    1_
$a Leníček, Martin $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine and General University Hospital in Prague, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000162423488 $7 xx0097551
773    0_
$w MED00007623 $t Liver international : official journal of the International Association for the Study of the Liver $x 1478-3231 $g Roč. 43, č. 4 (2023), s. 888-895
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36433660 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425140822 $b ABA008
999    __
$a ok $b bmc $g 1924408 $s 1189925
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 43 $c 4 $d 888-895 $e 20221125 $i 1478-3231 $m Liver international $n Liver Int $x MED00007623
LZP    __
$a Pubmed-20230418

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...